Yehia Mohamed
Ajman University, UAEPresentation Title:
COVID-19 outcomes in hospitalized diabetic patients in the UAE
Abstract
Background: Although we are four years into the pandemic, there is still conflicting evidence regarding the clinical outcomes of diabetic patients hospitalized with COVID-19. The primary objective of this study was to evaluate the in-hospital mortality and morbidity of diabetic versus nondiabetic patients hospitalized with COVID-19 in the Northern UAE’s Emirates.
Methods: A retrospective analysis was performed on clinical data from patients with or without diabetes mellitus (DM) who were admitted to the isolation hospital with COVID-19 during the first and second waves of the disease (March 2020-April 2021). The assessed endpoints were all-cause in-hospital mortality, length of hospitalization, intensive care unit (ICU) admission, and mechanical ventilation.
Results: A total of 427 patients were included in the analysis, of whom 335 (78.5%) had DM. Compared to nondiabetics, diabetic COVID-19 patients had a significantly longer in-hospital stay (13.9±13.1 vs. 9.4±8.3 days; p<0.001), as well as a significantly higher frequency of ICU admission (24.2% vs. 12.0%; p=0.01) and mechanical ventilation use (21.2% vs. 0.0%; p<0.001). The overall in-hospital mortality was significantly higher among diabetic patients (19.7%) compared to their nondiabetic counterparts (9.8%), p<0.05.
Conclusion: DM was associated with a more arduous course of COVID-19, including a higher mortality rate, a longer overall hospital stay, and a higher frequency of mechanical ventilation and ICU admission. Our results highlight the importance of DM control in COVID-19 patients to minimize the risk of detrimental clinical outcomes.
Biography
Yehia Mohamed is an associate professor of immunology. He gained his undergraduate degree from Al-Azhar University in Cairo, Egypt, and his PhD from the department of infection, immunity, and inflammation at Leicester University Medical School, UK (ranked 272nd worldwide according to the QS report 2024). Dr. Yehia received his training as a PDF at the Jenner Institute-Oxford University- UK, where he served as an immunology scientist to monitor the cellular responses to two HIV-vaccine clinical trials. As an academic, he is teaching journey spans many global destinations, including the Middle East, Europe, and North America, during which he focused on subject-oriented curriculum development, course coordination, student mentoring, and community service. He is interested in many areas of immunology and infectious disease research. These include developing vaccines for chronic respiratory and retroviruses, immunotherapy of tumors, exploring the immune-modulating effects of new medicines, and discovering and studying new natural bio-remedies with antimicrobial and antitumor potential.
Organization Location
#1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Drop us an email for Program enquiry
diabetes@scientexevents.com
General Queries
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
diabetes@scientexconferences.com
Our Social Presence
Call us at
USA :(+1) 307 464 7366